ZTS VS NVO Stock Comparison
Performance
ZTS100/100
100/100
ZTS returned 16.56% in the last 12 months. Based on SPY's performance of -13.45%, its performance is above average giving it a score of 100 of 100.
NVO100/100
100/100
NVO returned 70.22% in the last 12 months. Based on SPY's performance of -13.73%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
ZTS75/100
75/100
21 analysts offer 12-month price targets for ZTS. Together, they have an average target of 0, the most optimistic target put ZTS at 0 within 12-months and the most pessimistic has ZTS at 0.
NVO50/100
50/100
1 analysts offer 12-month price targets for NVO. Together, they have an average target of 0, the most optimistic target put NVO at 0 within 12-months and the most pessimistic has NVO at 0.
Technicals
ZTS82/100
82/100
ZTS receives a 82 of 100 based on 14 indicators. 11 are bullish, 2 are bearish.
NVO50/100
50/100
NVO receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.
Earnings
ZTS53/100
53/100
ZTS has missed earnings 2 times in the last 20 quarters.
NVO46/100
46/100
NVO has missed earnings 3 times in the last 20 quarters.
Profit
ZTS78/100
78/100
Out of the last 20 quarters, ZTS has had 19 profitable quarters and has increased their profits year over year on 11 of them.
NVO90/100
90/100
Out of the last 20 quarters, NVO has had 20 profitable quarters and has increased their profits year over year on 15 of them.
Volatility
ZTS50/100
50/100
ZTS has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
NVO53/100
53/100
NVO has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
Dividend
ZTS35/100
35/100
ZTS's most recent dividend was $0.12 per share, based on a share price of $174.62. It was a payout ratio of 17.39% compared to their total earnings.
NVO
"Dividend" not found for NVO
All score calculations are broken down here to help you make more informed investing decisions
ZOETIS INC. Summary
New York Stock Exchange / ZTS
Healthcare
Drug Manufacturers - Specialty & Generic
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Novo-Nordisk A/S Summary
New York Stock Exchange / NVO
Healthcare
Biotechnology
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ZTS to other companies in the same or a similar industry.